- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Alzheimer.
Displaying page 1 of 1.
| EudraCT Number: 2021-006336-94 | Sponsor Protocol Number: MK-1942-008 | Start Date*: 2022-10-24 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
| Full Title: A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia. | |||||||||||||
| Medical condition: Alzheimer’s Disease dementia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003398-87 | Sponsor Protocol Number: GN40040 | Start Date*: 2019-05-30 | |||||||||||
| Sponsor Name:Roche Farma, S.A por delegación de Genentech, Inc. | |||||||||||||
| Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH MODERATE ALZHEIMER’S DISEASE | |||||||||||||
| Medical condition: Alzheimer’s disease (AD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-003532-23 | Sponsor Protocol Number: PBD01180 | Start Date*: 2020-06-26 | |||||||||||
| Sponsor Name:Vivoryon Therapeutics N.V. | |||||||||||||
| Full Title: A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects with Mild Cognitive Impairment and Mi... | |||||||||||||
| Medical condition: Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) DE (Completed) NL (Completed) ES (Ongoing) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005829-88 | Sponsor Protocol Number: AH0003 | Start Date*: 2021-09-28 | |||||||||||
| Sponsor Name:UCB Biopharma SRL | |||||||||||||
| Full Title: A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disea... | |||||||||||||
| Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-000370-27 | Sponsor Protocol Number: COR388-010-UK | Start Date*: 2019-10-24 | |||||||||||
| Sponsor Name:Cortexyme, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer’s Disease | |||||||||||||
| Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005263-16 | Sponsor Protocol Number: NSC15001 | Start Date*: 2016-07-11 | ||||||||||||||||
| Sponsor Name:Pharmatrophix Inc | ||||||||||||||||||
| Full Title: A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate safety, tolerability and exploratory endpoints of either placebo or two d... | ||||||||||||||||||
| Medical condition: Mild to moderate Alzheimer's disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Completed) CZ (Completed) DE (Completed) SE (Completed) ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-004290-84 | Sponsor Protocol Number: tau-PET/BBRC2019 | Start Date*: 2020-04-29 |
| Sponsor Name:BarcelonaBeta Brain Research Center | ||
| Full Title: Characterization of cerebral tau aggregates with 18F-RO6958948 PET in the ALFA population. | ||
| Medical condition: Alzheimer's Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000307-17 | Sponsor Protocol Number: DIAN-TU-001 | Start Date*: 2014-01-08 |
| Sponsor Name:Washington University in St. Louis | ||
| Full Title: A Phase II/III randomized, double-blind, placebo-controlled, cognitive endpoint, multicenter study of potential disease modifying therapies in individuals at risk for and with dominantly inherited ... | ||
| Medical condition: Dominantly Inherited Alzheimer Disease (DIAD) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) ES (Temporarily Halted) DE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003567-66 | Sponsor Protocol Number: T817MAEU201 | Start Date*: 2019-06-11 | ||||||||||||||||
| Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd. | ||||||||||||||||||
| Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer... | ||||||||||||||||||
| Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-000473-83 | Sponsor Protocol Number: PET-tau-FACEHBI | Start Date*: 2021-12-15 |
| Sponsor Name:Fundació ACE-Institut Català de Neurociències Aplicades | ||
| Full Title: PET imaging study of the brain tau deposit in individuals with subjective cognitive decline and mild cognitive impairment: FACEHBI cohort. | ||
| Medical condition: Subjective cognitive impairment and mild cognitive decline in evaluation for diagnosis of Alzheimer's Disease. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003558-17 | Sponsor Protocol Number: TRx-237-039 | Start Date*: 2018-02-25 | |||||||||||
| Sponsor Name:TauRx Therapeutics Ltd | |||||||||||||
| Full Title: Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12... | |||||||||||||
| Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) ES (Ongoing) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002843-11 | Sponsor Protocol Number: BAN2401-G000-201 | Start Date*: 2013-04-26 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With E... | |||||||||||||
| Medical condition: Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) ES (Temporarily Halted) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002987-57 | Sponsor Protocol Number: AL002-LTE | Start Date*: 2023-03-09 | |||||||||||
| Sponsor Name:Alector Inc. | |||||||||||||
| Full Title: A Multicenter, Long-Term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer’s Disease | |||||||||||||
| Medical condition: Early Alzheimer's Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002568-62 | Sponsor Protocol Number: AVB-PGRN-001 | Start Date*: 2023-03-13 |
| Sponsor Name:AviadoBio Ltd | ||
| Full Title: A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal... | ||
| Medical condition: Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) IT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) BE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-002251-11 | Sponsor Protocol Number: TPN-101-C9-201 | Start Date*: 2021-12-06 | ||||||||||||||||
| Sponsor Name:Transposon Therapeutics, Inc | ||||||||||||||||||
| Full Title: A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia) | ||||||||||||||||||
| Medical condition: Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 hexanucleotide repeat expansion | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) FR (Completed) ES (Ongoing) BE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.